Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study

Vitale, Alessandro; Morales, Rafael; Zanus, Giacomo; Farinati, Fabio; Burra, Patrizia; Angeli, Paolo; Frigo, Anna Chiara; Poggio, P. Del; Rapaccini, Gianludovico; Nolfo, Maria Anna Di; Benvegnù, Luisa; Zoli, Marco; Borzio, Franco; Giannini, Edoardo G.; Caturelli, Eugenio; Chiaramonte, M.; Trevisani, Franco; Cillo, Umberto

doi:10.1016/s1470-2045(11)70144-9

Cited by 144 publications

(120 citation statements)

References 23 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…Similarly, Gu-glielmi et al (2008) also compared the same seven staging systems and confirmed that the BCLC system was superior to the other six systems when evaluated in a cohort of 112 HCC patients who underwent radiofrequency ablation (RFA). Although the BCLC system has been prospectively validated in an Italian cohort of 195 HCC patients treated mainly with radical therapies (Cillo et al 2006), there have been controversies surrounding the BCLC system, particularly in its application in surgical treatment for HCC patients (Ishizawa et al 2008;Torzilli et al 2008;Vitale et al 2011). Nevertheless, the BCLC system has provided an algorithmic approach for the treatment of liver cancer, and new treatments can be tested in different stratification groups.…”

Section: Bclc Staging Systemmentioning

confidence: 99%

Treatment of Liver Cancer

Liu

Chen

2015

Cold Spring Harb Perspect Med

298

198

View full text Add to dashboard Cite

Primary liver cancer, mostly hepatocellular carcinoma, remains a difficult-to-treat cancer. Incidence of liver cancer varies geographically and parallels with the geographic prevalence of viral hepatitis. A number of staging systems have been developed, reflecting the heterogeneity of primary liver cancer, regional preferences, and regional variations in resectability or transplant eligibility. Multimodality treatments are available for this heterogeneous malignancy, and there are variations in the management recommendations for liver cancers across specialties and geographic regions. Novel treatment strategies have merged with the advance of new treatment modalities. This work focuses on reviewing the incidence, staging, and treatment of liver cancer.

show abstract

Section: Bclc Staging Systemmentioning

confidence: 99%

Treatment of Liver Cancer

Liu

Chen

2015

Cold Spring Harb Perspect Med

298

198

View full text Add to dashboard Cite

show abstract

“…The appropriate selection of candidates with or without HCC for LT, and their priority on the waiting list, therefore cannot be achieved with models based on urgency alone (Appendix 1). The principles of urgency and utility must be balanced and integrated with transplant benefit (5).…”

Section: Introductionmentioning

confidence: 99%

A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a “Blended Principle Model”

Cillo

Burra

Mazzaferro

et al. 2015

American Journal of Transplantation

184

129

View full text Add to dashboard Cite

“…We confirmed these findings, calculating the expected gain in life expectancy of LT versus non-transplant therapies for patients stratified by BCLC stage. We found that in patients with BCLC stage A the 5-year transplant benefit was only 13.5 months, whereas it was 17.4 months in patients with BCLC stage B or C, and 28.5 months in patients with BCLC stage D [24].…”

Section: The Transplant Benefit As An Endpointmentioning

confidence: 68%

Surgery and Hepatocellular Carcinoma

et al. 2016

Self Cite

View full text Add to dashboard Cite

The optimal surgical strategy for hepatocellular carcinoma (HCC) is under active debate. Bio-markers of the liver functional reserve as well as volumetric analysis of the future liver remnant are essential for safe liver resection of HCC. The present algorithms applied to surgical strategies for HCC are not ideal because many patients who could potentially undergo safe resection are deemed liver transplant candidates in Western countries, whereas the opposite is the case in Eastern countries. In addition, there is too much focus on expanded criteria for patients with HCC to undergo liver transplantation. The transplantation benefit for patients with HCC should be considered based not only on the individual's benefit, but also on the effect of other patients waiting for LT for other indications.

show abstract

Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study

Cited by 144 publications

References 23 publications

Treatment of Liver Cancer

Treatment of Liver Cancer

A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a “Blended Principle Model”

Surgery and Hepatocellular Carcinoma

Contact Info

Product

Resources

About